Cargando…
Gene Therapy in Thalassemia and Hemoglobinopathies
Sickle cell disease (SCD) and ß-thalassemia represent the most common hemoglobinopathies caused, respectively, by the alteration of structural features or deficient production of the ß-chain of the Hb molecule. Other hemoglobinopathies are characterized by different mutations in the α- or ß-globin g...
Autores principales: | Breda, Laura, Gambari, Roberto, Rivella, Stefano |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033156/ https://www.ncbi.nlm.nih.gov/pubmed/21415990 http://dx.doi.org/10.4084/MJHID.2009.008 |
Ejemplares similares
-
Recent trends in the gene therapy of β-thalassemia
por: Finotti, Alessia, et al.
Publicado: (2015) -
EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update
por: Iolascon, Achille, et al.
Publicado: (2019) -
Infections in Thalassemia and Hemoglobinopathies: Focus on Therapy-Related Complications
por: Ricerca, Bianca Maria, et al.
Publicado: (2009) -
A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction
por: Zuccato, Cristina, et al.
Publicado: (2012) -
Prenatal Diagnosis of β-Thalassemias and Hemoglobinopathies.
por: Rosatelli, Maria Cristina, et al.
Publicado: (2009)